Dexcom (DXCM) Share-based Compensation (2010 - 2026)

Dexcom (DXCM) has 17 years of Share-based Compensation data on file, last reported at $43.3 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $43.3 million, up 26.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $168.7 million (up 1.87% YoY), and the FY2025 annual result was $159.6 million, down 6.34% from the prior year.
• Share-based Compensation rose to $43.3 million in Q1 2026 per DXCM's latest filing, from $35.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $45.3 million in Q2 2025 and troughed at $29.1 million in Q1 2022.
• A 5-year average of $38.3 million and a median of $39.0 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation climbed 29.28% in 2022, then decreased 19.17% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $34.0 million in 2022, then increased by 8.53% to $36.9 million in 2023, then grew by 17.34% to $43.3 million in 2024, then slipped by 19.17% to $35.0 million in 2025, then advanced by 23.71% to $43.3 million in 2026.
• Business Quant data shows DXCM's Share-based Compensation at $43.3 million in Q1 2026, $35.0 million in Q4 2025, and $45.1 million in Q3 2025.